Fund Insights
Common Fund Bets
See what stocks and ETFs funds are collectively bullish/bearish on
Largest Fund Trades
Explore the largest stock and ETF buys and sells made by funds
Fund Manager Portfolios
Gain insights from the world's largest funds and super investors
Analyst Insights
Price Target Consensus
See what stocks research analysts are collectively bullish/bearish on
Latest Ratings Feed
Explore the latest ratings and price targets from the best equity research analysts
Equity Analyst Profiles
Browse analysts, their latest ratings and track record
Research Firm Profiles
Browse research firm recommendations, trends, and performance
WSR Indexes
Fund Manager Index
Stock index based on fund manager consensus updated each quarter
Analyst Index
COMING SOON - Stock index based on equity analyst consensus updated every second
Search
Sign in
Sign up
LeMaitre Vascular
LMAT
Market cap
$1.98B
Overview
Fund Trends
Analyst Outlook
Journalist POV
87.26
USD
--0.12
0.14%
At close
Updated
Oct 15, 4:00 PM EDT
Pre-market
After hours
87.26
0.00
0%
1D
5D
1M
3M
6M
YTD
1Y
5Y
10Y
1 day
-0.14%
5 days
-1.18%
1 month
-5.53%
3 months
6.12%
6 months
3.11%
Year to date
-4.6%
1 year
-4.36%
5 years
172.69%
10 years
603.71%
Positive
Neutral
Negative
Sentiment
3-Months
Positive
Neutral
40%
Negative
Positive
Neutral
Negative
Neutral
GlobeNewsWire
5 days ago
LeMaitre Will Announce Third Quarter 2025 Earnings Results on November 6, 2025
BURLINGTON, Mass., Oct. 09, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its third quarter 2025 financial results on Thursday, November 6, 2025, after the market close.
Positive
Seeking Alpha
29 days ago
LeMaitre Vascular: Investment Debate Remains In Place
LeMaitre Vascular remains a long-term compounder, delivering strong Q2 results with 15% sales growth, robust margins, and increased dividends. LMAT's investment thesis is supported by pricing power, an expanding product pipeline, disciplined capital allocation, and consistent reinvestment driving high returns on capital. Valuation is fair-to-full at current levels, with a $110-$111 price target; compounding will come from intrinsic value growth rather than multiple expansion.
Neutral
GlobeNewsWire
1 month ago
LeMaitre to Participate at Upcoming Investor Conferences in September
BURLINGTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in four upcoming investor conferences.
Positive
Zacks Investment Research
1 month ago
Is LeMaitre (LMAT) a Solid Growth Stock? 3 Reasons to Think "Yes"
LeMaitre (LMAT) possesses solid growth attributes, which could help it handily outperform the market.
Positive
Zacks Investment Research
2 months ago
LeMaitre (LMAT) is an Incredible Growth Stock: 3 Reasons Why
LeMaitre (LMAT) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Positive
The Motley Fool
2 months ago
LeMaitre (LMAT) Q2 Revenue Jumps 15%
LeMaitre (LMAT) Q2 Revenue Jumps 15%
Neutral
Seeking Alpha
2 months ago
LeMaitre Vascular, Inc. (LMAT) Q2 2025 Earnings Call Transcript
LeMaitre Vascular, Inc. (NASDAQ:LMAT ) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants David B. Roberts - President & Director Dorian LeBlanc - Chief Financial Officer George W.
Positive
Zacks Investment Research
2 months ago
LeMaitre Vascular (LMAT) Beats Q2 Earnings and Revenue Estimates
LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.6 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.52 per share a year ago.
Neutral
GlobeNewsWire
2 months ago
LeMaitre Q2 2025 Financial Results
BURLINGTON, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q2 2025 results, announced a quarterly dividend of $0.20/share, and provided guidance.
Positive
Zacks Investment Research
2 months ago
PAHC vs. LMAT: Which Stock Should Value Investors Buy Now?
Investors with an interest in Medical - Products stocks have likely encountered both Phibro Animal Health (PAHC) and LeMaitre Vascular (LMAT). But which of these two stocks presents investors with the better value opportunity right now?
Show more
See News Rankings
Sign up
Sign in
Fund Insights
Common Fund Bets
See what stocks and ETFs funds are collectively bullish/bearish on
Largest Fund Trades
Explore the largest stock and ETF buys and sells made by funds
Fund Manager Portfolios
Gain insights from the world's largest funds and super investors
Analyst Insights
Price Target Consensus
See what stocks research analysts are collectively bullish/bearish on
Latest Ratings Feed
Explore the latest ratings and price targets from the best equity research analysts
Equity Analyst Profiles
Browse analysts, their latest ratings and track record
Research Firm Profiles
Browse research firm recommendations, trends, and performance
WSR Indexes
Fund Manager Index
Stock index based on fund manager consensus updated each quarter
Analyst Index
COMING SOON - Stock index based on equity analyst consensus updated every second
Theme
Close